Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 91   

Articles published

DVAX 15.34 -0.18 (-1.16%)
price chart
Company Update on High Short Interest: Dynavax Technologies Corp ...
Dynavax Technologies Corp (NASDAQ:DVAX): Each share of Dynavax Technologies Corp is priced at $15.91, which is 25.7% below the 52-week high.
Related articles »  
Cowen and Company Reiterates "Outperform" Rating for Dynavax Technologies ...
Dynavax Technologies logo Dynavax Technologies (NASDAQ:DVAX)'s stock had its �outperform� rating reiterated by stock analysts at Cowen and Company in a report issued on Friday. They currently have a $60.00 price objective on the stock, up from their ...
Don't Miss These Stocks: Burger King Worldwide (NYSE:BKW), Cirrus Logic ...  Property Mentor
Related articles »  
Dynavax: Assembling The A-Team
As I noted earlier this year, on Thursday, March 21, 2013, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that David Novack joined the company as its Senior Vice President, Operations and Quality, effective March 25, 2013.
Related articles »  
Hedge Funds Are Crazy About Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation To the average investor, there are dozens of gauges shareholders can use to track publicly traded companies.
Dynavax: FDA Asks For Additional Safety Data  Seeking Alpha
Dynavax's hepatitis B vaccine delayed as FDA seeks more data  Reuters
Related articles »  
Dynavax Technologies Corporation (DVAX): Dynavax: Embarking On A Run ...
Dynavax (NASDAQ:DVAX) will require a lot of patience. The stock will require about as much patience as has ever been asked of you as an investor.
Dynavax Technologies Corporation (DVAX) news: Dynavax drops request for ...
Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less ...
Dynavax Withdraws MAA on Heplisav  Zacks.com
Dynavax Withdraws MAA on Heplisav - Analyst Blog  NASDAQ
Related articles »  
Dynavax Technologies Corporation (DVAX): Getting Ultra-Bullish On Dynavax
Dynavax Technologies Corporation is a clinical-stage biopharma that develops novel products to prevent and treat infectious and inflammatory diseases and cancer.
Related articles »  
Dynavax Technologies Corporation (DVAX): Insiders Are Buying Dynavax
In Europe, Dynavax' Marketing Authorization Application for Heplisav is currently under review by the European Medicines Agency.
Dynavax: A Compelling Buy
Dynavax Technologies Corporation (NASDAQ:DVAX) recently received some unfavorable news from the FDA in that the agency refused to accept its Hepatitis Drug Heplisav.
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Dynavax ...
... LLP (www.rmclasslaw.com/cases/dvax) announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of Dynavax Technologies Corporation ("Dynavax" or the ...
Related articles »